2025 First Quarter SalesPress release – Paris, April 23, 2025, at 7:30am CEST Strong start to the year,demonstrating the relevance of our health-oriented portfolio Strong Q1 2025, with sales of €6,844m, up +4.3% on a like-for-like (LFL) basisContributions from both volume/mix (+1.9%) and price (+2.4%); positive volume/mix again in all categoriesBroad-based growth, demonstrating the resilience of our business Very strong performance in China, North Asia & Oceania, in all categoriesSolid growth in North Ame ...

Core Insights - Corbion reported strong Q1 2025 results, with significant growth in sales and adjusted EBITDA, affirming its full-year outlook [1][5] Financial Performance - Organic sales growth of 7.9% driven by volume/mix growth of 8.4%, while prices decreased by 0.5% [2] - Total sales reached €329.7 million, up 9.8% from €300.4 million in Q1 2024 [2] - Adjusted EBITDA increased to €54.4 million, reflecting a 57.7% rise, with an organic increase of 53.9% [2][5] - Operating profit surged to €34.0 million, marking a 193.1% increase, with an organic growth of 186.2% [2][5] - Adjusted EBITDA margin improved to 16.5%, up from 11.5% in the previous year [2] Business Segments Performance - In Functional Ingredients & Solutions, all three businesses (Food, Biochemicals, and Lactic acid to the PLA JV) achieved volume/mix growth, with margins exceeding 12% [3] - Health & Nutrition segment also saw volume/mix growth across all three businesses (Nutrition, Biomedical polymers, and Pharma), with adjusted EBITDA margins exceeding 30% [3] Strategic Outlook - The company remains committed to executing its strategy amidst macro-economic and geopolitical uncertainties, on track to meet 2025 guidance for volume/mix, adjusted EBITDA, and free cash flow [4]

Core Insights - Vopak reported strong Q1 2025 results with a net profit of EUR 100 million and earnings per share (EPS) of EUR 0.85, maintaining stable performance year-on-year [2][7] - The company is expanding its capacity and investing in growth projects, including a significant expansion in Thailand and partnerships in Oman [2][3] Financial Performance - Revenues for Q1 2025 were EUR 328.9 million, slightly up from EUR 328.2 million in Q1 2024 [1][7] - Proportional revenues increased to EUR 488.4 million, driven by growth projects and positive currency effects [1][7] - Proportional EBITDA rose to EUR 299.9 million, reflecting contributions from growth projects [1][7] - Cash flows from operating activities increased to EUR 305.9 million, up from EUR 278.8 million in Q1 2024 [1][7] Operational Highlights - Storage capacity at the end of Q1 2025 was 35.6 million cubic meters, an increase from 34.8 million cubic meters in Q1 2024 [1][6] - The subsidiary occupancy rate was 91%, slightly down from 92% in Q1 2024, attributed to weak market conditions in specific regions [1][6] - Proportional operating cash return remained stable at 16.8% compared to 17.0% in Q1 2024 [1][13] Strategic Developments - Vopak signed agreements for a new debt issuance of around EUR 560 million, enhancing its financial flexibility [2] - The company is planning to invest an additional EUR 1 billion in gas and industrial terminals by 2030, aiming for a total of EUR 2 billion [3] - Vopak is developing battery energy storage infrastructure through the acquisition of a battery development company in the Netherlands [2]

Core Insights - DNO ASA will release its Q1 2025 operating and interim financial results on May 15, 2025, followed by a videoconference with executive management [1] Production and Sales Volumes - Gross operated production in Kurdistan for Q1 2025 was 82,081 barrels of oil equivalent per day (boepd), an increase from 74,163 boepd in Q4 2024 and 76,310 boepd in Q1 2024 [2] - North Sea production reached 8,864 boepd in Q1 2025, up from 6,602 boepd in Q4 2024 [2] - Net entitlement production in Kurdistan was 18,464 boepd for Q1 2025, compared to 17,424 boepd in Q4 2024 and 20,503 boepd in Q1 2024 [2] - North Sea net entitlement production was 19,296 boepd in Q1 2025, slightly up from 19,031 boepd in Q4 2024 and significantly higher than 14,217 boepd in Q1 2024 [2] - Sales volumes in Kurdistan for Q1 2025 matched net entitlement production at 18,464 boepd, while North Sea sales were 16,981 boepd, down from 17,088 boepd in Q4 2024 [2] Financial Highlights - DNO paid a dividend of NOK 0.3125 per share in Q1 2025, totaling USD 27.4 million, which annualizes to NOK 1.25 per share [4] - The company made no tax payments or refunds during the quarter [4] - DNO announced the acquisition of Sval Energi Group AS in early March, paying a deposit of USD 22.5 million, with completion expected mid-2025 [4] - A private placement of USD 600 million in new five-year senior unsecured bonds was completed in March 2025 [5] - Early redemption of another bond, DNO04, was completed on April 10, 2025, without impacting Q1 2025 cash flow [5] Exploration Activities - DNO participated in two discoveries on the Norwegian Continental Shelf during Q1 2025, with combined recoverable resources of 26 million barrels of oil equivalent net to DNO [6] - The Mistral well in PL1119 and the Kjøttkake well in PL1182 S were successfully completed, while the Horatio well in PL1109 was dry [6]

Core Viewpoint - Coop Pank demonstrated growth in customer base, deposits, and loan portfolio in Q1 2025, despite a slight decrease in net income compared to previous periods [1][5][6]. Customer Growth - By the end of Q1 2025, Coop Pank had 213,000 customers, an increase of 5,000 customers in the quarter (+2%) and 23,000 in the year (+12%) [1]. - The number of active customers reached 101,800, with an increase of 2,400 (+3%) in the quarter and 17,400 (+21%) year-over-year [1]. Deposit Volume - In Q1 2025, the volume of deposits decreased by 29 million euros, totaling 1.91 billion euros, but increased by 221 million euros (+13%) compared to Q1 2024 [2]. - Deposits from private clients increased by 15 million euros, while deposits from domestic business customers rose by 39 million euros [2]. - The share of demand deposits in total deposits increased from 30% to 32% year-over-year [2]. Loan Portfolio - The net loan portfolio increased by 44 million euros (+3%) in Q1 2025, reaching 1.81 billion euros, with business and home loans showing the most significant growth [3]. - Compared to Q1 2024, the total loan portfolio grew by 287 million euros (+19%) [3]. Asset Quality - The overdue loan portfolio remained steady at 2.1%, down from 2.4% a year ago [4]. - Impairment costs of financial assets were 0.2 million euros, significantly lower than previous quarters [4]. Financial Performance - Net income for Q1 2025 was 19.3 million euros, a decrease of 3% quarter-over-quarter and 5% year-over-year [5]. - Net profit was 7.9 million euros, which is 24% higher than the previous quarter but 13% lower than a year ago [6]. - The cost-to-income ratio was 49%, and return on equity was 14.7% [6][10]. Market Position - Coop Pank held a 6.3% market share in deposits and a 6.6% share in loans by the end of Q1 2025 [9]. - The bank's growth in business volumes was at twice the rate of market growth [9]. Strategic Developments - In March 2025, Coop Pank issued covered bonds for the first time on the Irish Stock Exchange, amounting to 250 million euros, as part of a 750 million euros program [11][12]. - This issuance provides an additional long-term funding source to support business growth in Estonia [12]. Management Commentary - The Chairman of the Management Board noted positive signs in the economic environment but expressed concerns about declining confidence among local businesses due to trade wars [7][8].

Core Insights - Roche has introduced an innovative Chest Pain Triage algorithm as part of the navifyⓇ Algorithm Suite, aimed at improving the detection of Acute Coronary Syndrome (ACS) in patients with chest pain, a common reason for Emergency Department visits [1][3][7] Group 1: Algorithm Features - The Chest Pain Triage algorithm utilizes advanced diagnostic technologies, including high-sensitivity cardiac troponin testing, to provide timely and reliable data for differentiating between cardiac and non-cardiac chest pain [2][4] - It incorporates European Society of Cardiology (ESC) guidelines and was developed with input from leading cardiologists and emergency medicine experts [2][4] - The algorithm simplifies decision-making by automatically selecting the appropriate ESC accelerated pathway based on blood sample timing, potentially reducing unnecessary hospital admissions and associated costs [3][4] Group 2: Impact on Emergency Care - The algorithm aims to reduce Emergency Department visit times by over three hours by quickly identifying patients who need urgent cardiac care versus those who can be discharged sooner [3][4] - It includes a medical dossier for clinician support and simplifies documentation, allowing for easy integration into patient records [3][4] Group 3: Availability and Future Developments - The Chest Pain Triage algorithm is currently available in Europe, the Middle East, and Asia, with plans for availability in the United States at a later date [4][5] - Roche's cardiometabolic portfolio will continue to evolve, combining next-generation digital algorithms, biomarkers, near-patient care devices, and laboratory analyzers for enhanced ACS management [4][5]

Company Overview - VERAXA Biotech AG is an emerging leader in designing novel cancer therapies, focusing on a comprehensive pipeline of next-generation cancer therapies through its proprietary Bi-Targeted Antibody Cytotoxicity (BiTAC) technology platform [1][2] - The company is advancing a premier drug discovery and development engine for antibody-drug conjugates (ADCs) and other novel antibody-based therapy concepts [2] Business Combination - VERAXA has entered into a definitive business combination agreement with Voyager Acquisition Corp, which will create a publicly traded clinical-stage biopharmaceutical company [1] - The transaction values VERAXA at a pre-money equity value of $1.3 billion, with existing shareholders receiving approximately 130 million ordinary shares of the combined company [6][10] - The business combination is expected to close in the fourth quarter of 2025, subject to shareholder approval and customary closing conditions [13] Market Potential - The global TCE market is projected to reach $112 billion by 2030, with a compound annual growth rate (CAGR) of over 44%, while the global ADC market is expected to reach $57 billion by 2030, with a CAGR close to 30% [3] - The company aims to address the limitations of current cancer therapies by developing next-generation therapies with improved safety and efficacy profiles [4] Pipeline and Development - VERAXA's pipeline includes nine discovery and development programs at various stages, with the most advanced asset, VX-A901, showing potent anti-cancer activity [4] - The company is pursuing both internal innovation and strategic partnerships to enhance its pipeline, anticipating three proprietary development programs in the clinic by 2029 [4][6] Leadership and Support - The leadership team includes experienced professionals such as CEO Christoph Antz, Ph.D., and CBO Heinz Schwer, Ph.D., MBA, both of whom have backgrounds in venture capital [5] - The company is supported by international scientific advisors, including experts in immuno-oncology [8] Financial Strategy - VERAXA is actively raising a crossover financing round expected to close before the business combination, which will provide sufficient capital for the next two years [12] - Upon closing, the combined entity is expected to have an implied pro forma equity value of approximately $1.64 billion, with access to up to $253 million in cash held in trust by Voyager [11]

Core Insights - The 20th China Huabiao Film Awards Ceremony will be held in Qingdao on April 27, 2025, to celebrate the 120th anniversary of Chinese cinema [1][3] - This year's awards aim to promote high-quality development in Chinese filmmaking, coinciding with the international success of "Ne Zha 2," which has entered the top five in global box office history [4] Event Details - The ceremony is organized by the China Film Administration and will be the first time it takes place in Qingdao, gathering representatives from the film industry and audiences nationwide [3][4] - The visual design of the awards ceremony features a coiled dragon motif, symbolizing the journey and aspirations of Chinese filmmakers, with elements representing the era's dynamic spirit [5] Industry Impact - The event is expected to showcase the unity and creative spirit of Chinese filmmakers, contributing to the revitalization of the Chinese cinema industry [6]

Core Viewpoint - Sayona Mining Limited is progressing with a proposed transaction to merge with Piedmont Lithium Inc., aiming to create a leading lithium business, subject to shareholder approval [1][2]. Group 1: Transaction Details - Upon completion of the transaction, the company will be renamed Elevra Lithium Limited, with shareholders of Sayona and Piedmont Lithium holding approximately 50% equity each in the new entity [2]. - Significant regulatory approvals have been obtained, including Investment Canada Act approval, Hart-Scott-Rodino Act approval, and a review by the Committee on Foreign Investment in the United States, which has concluded without further action [3]. - The transaction is targeted to close in mid-CY2025, pending shareholder approval and customary conditions [4]. Group 2: Share Consolidation and Financial Implications - Sayona plans to consolidate its shares at a ratio of 150:1 and will issue American Depositary Shares at a ratio of 10:1 post-consolidation, contingent on shareholder approval [4][5]. - Based on the current share price of A$0.017 and the AUD:USD exchange rate of 0.64, the post-consolidation share price is projected to be approximately A$2.55, with indicative ADS pricing around US$16.32 [5]. Group 3: Management Perspective - The Managing Director and CEO of Sayona expressed confidence that the merger will position Elevra Lithium as a leader in the lithium sector, contributing to the global energy transition [7][9].

Core Insights - The 2025 Data Breach Investigations Report (DBIR) reveals a significant increase in global data breaches, particularly in the EMEA region, where system intrusion breaches have nearly doubled to 53% [1][7] - The report analyzed over 22,000 security incidents, including 12,195 confirmed data breaches, highlighting a 34% increase in vulnerability exploitation globally and a doubling of third-party involvement to 30% [2][6] - EMEA shows a high percentage of breaches originating from internal actors at 29%, contrasting sharply with APAC and North America, where internal threats account for only 1% and 5% respectively [2][3] Key EMEA Findings - System intrusion breaches surged to 53%, nearly double last year's rate of 27% [7] - Insider leaks account for 29% of breaches in EMEA, with 19% due to unintentional mistakes and 8% from misuse [7] - Social engineering incidents, particularly phishing, were involved in 19% of breaches in EMEA [7] Key Global Findings - Ransomware attacks increased by 37% since last year, now present in 44% of breaches, despite a decrease in the median ransom amount paid [7] - The manufacturing sector experienced a nearly sixfold increase in espionage-motivated breaches, rising to 20% from just 3% last year [6][7] - Human involvement in breaches remains high, with significant overlap between social engineering and credential abuse [7]